Cases & Deals

  • Home
  • Practices
  • Junshi Biosciences forms joint venture with Rxilient Biotech to develop and commercialize toripalimab in Southeast Asia

Share

Junshi Biosciences forms joint venture with Rxilient Biotech to develop and commercialize toripalimab in Southeast Asia

March 2023

Client(s) Junshi Biosciences

Jones Day advised Junshi Biosciences in the formation of a joint venture company, Excellmab, with Rxilient Biotech to develop and commercialize toripalimab, an anti-PD-1 monoclonal antibody drug, in nine Southeast Asian countries.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.